Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The novel mechanism of lenalidomide activity

5 Oct 2015

Abstract excerpt

Lenalidomide acts by a novel drug mechanism-modulation of the substrate specificity of the CRL4(CRBN) E3 ubiquitin ligase. In multiple myeloma, lenalidomide induces the ubiquitination of IKZF1 and IKZF3 by CRL4(CRBN). Subsequent proteasomal degradation of these transcription factors kills multiple myeloma cells. In del(5q) myelodysplastic syndrome, lenalidomide induces the degradation of CK1α, which...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Multiple Myeloma Research and Treatments
Share to Protein Degradation and Inhibitors
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26438514
DOI: 10.1182/blood-2015-07-567958

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The novel mechanism of lenalidomide activityPMID 26438514Read ↗

Novel Molecular Mechanism of Lenalidomide in Myeloid Malignancies Independent of Deletion of Chromosome 5qSemantic proximity Read ↗

Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma CellsSemantic proximity Read ↗

Novel immunomodulatory drugs and neo-substratesSemantic proximity Read ↗

Genome-wide screening reveals a role for subcellular localization of CRBN in the anti-myeloma activity of pomalidomideSemantic proximity Read ↗

Key regulators of sensitivity to immunomodulatory drugs in cancer treatmentSemantic proximity Read ↗

Loss of lenalidomide-induced megakaryocytic differentiation leads to therapy resistance in del(5q) myelodysplastic syndrome.Semantic proximity Read ↗

UBE2G1 Governs the Destruction of Cereblon Neomorphic SubstratesSemantic proximity Read ↗

Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletionSemantic proximity Read ↗

The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros ProteinsSemantic proximity Read ↗

Crbn I391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in miceSemantic proximity Read ↗

Mechanisms of lenalidomide sensitivity and resistanceSemantic proximity Read ↗

A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomideSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.